加载中
NASDAQHealthcareBiotechnology
最新数据
US$3.31
−US$0.11 · -3.22%
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
前收盘价
US$3.31
−US$0.11 · -3.22%
盘前
US$3.60
+US$0.29 · +8.76%
10月12日 4:47 ET
盘中时间采用ET。市场数据可能有所延迟。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日内区间
当前US$3.31
52周区间
当前US$3.31
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
51
合理估值
情绪
63
看涨
风险
60
风险偏高
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
日内区间
当前US$3.31
52周区间
当前US$3.31
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.21亿 USD | 7310.7万 USD | 5628.6万 USD | — | — |
| 销售、一般及管理费用 | 2462万 USD | 775.6万 USD | 848.5万 USD | 3520 USD | 4.34万 USD |
| 营业费用 | 1.46亿 USD | 8086.3万 USD | 6477.1万 USD | 3520 USD | 4.34万 USD |
| 利息收入 | 1134.3万 USD | 637.7万 USD | 7.2万 USD | — | — |
| 折旧和摊销 | 61万 USD | 20.8万 USD | 9.2万 USD | 3520 USD | — |
| 营业利润 | −1.46亿 USD | −8086.3万 USD | −6477.1万 USD | −3520 USD | −4.34万 USD |
| 净利润 | −1.34亿 USD | −7427.5万 USD | −6469.9万 USD | −3520 USD | −4.34万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1252.15万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF491.01万0.01%954亿 USD0.05%US$235+0.80%
State Street SPDR S&P Biotech ETFXBI228.24万0.02%98.74亿 USD0.35%US$153.77+3.00%
iShares Biotechnology ETFIBB126.83万0.01%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA77.75万0.00%218.24亿 USD0.03%US$32.79+0.40%
Virtus Biotech Clinical Trials ETFBBC14万0.34%4099.65万 USD0.65%US$44.1456+2.08%
Direxion Daily S&P Biotech Bull 3X SharesLABU10.79万0.02%5.97亿 USD0.96%US$243.09+9.01%
Schwab U.S. Broad Market ETFSCHB9.48万0.00%453.77亿 USD0.03%US$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVirtus Biotech Clinical Trials ETFBBCDirexion Daily S&P Biotech Bull 3X SharesLABUSchwab U.S. Broad Market ETFSCHBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
